Premium
Shattuck Labs Inc (STTK)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Dr. Clay B. SiegallIndependent Director | 128,05k | 138,89k | Derivative Exercise and Retained Stock | 1,08 | 256,11k | 100,00% |
| 2026-05-21 | Dr. Abhinav A. ShuklaChief Technical Officer | 5,12k | 5,56k | Derivative Exercise and Retained Stock | 1,08 | 86,38k | 6,30% |
| 2026-05-12 | Dr. Abhinav A. ShuklaChief Technical Officer | -2,03k | 6,99k | Derivative Exercise and Sale | 3,57 - 7,01 | 81,26k | - |
| 2026-05-12 | Dr. Arunthathy Nirmalini PanditeChief Medical Officer | -30,00k | 198,30k | Automatic Disposition | 6,61 | 166,22k | -15,29% |
| 2026-05-12 | Dr. Taylor H. SchreiberCo-Founder, CEO & Director | 25,61k | 27,78k | Derivative Exercise and Retained Stock | 1,08 | 2,73M | 0,95% |
| 2026-05-10 | Dr. Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | -968,00 | 6,63k | Sale to Issuer | 6,85 | 80,56k | -1,19% |
| 2026-01-25 | Dr. Arunthathy Nirmalini PanditeChief Medical Officer | -3,20k | 13,26k | Sale to Issuer | 4,15 | 163,51k | -1,92% |
| 2026-01-25 | Dr. Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | -593,00 | 2,46k | Sale to Issuer | 4,15 | 81,53k | -0,72% |
| 2026-01-25 | Ms. Casi DeYoungChief Business Officer | -2,29k | 9,49k | Sale to Issuer | 4,15 | 43,61k | -4,98% |
| 2026-01-25 | Mr. Andrew R. NeillCFO | -2,59k | 10,74k | Sale to Issuer | 4,15 | 191,24k | -1,34% |
| 2026-01-10 | Dr. Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | -4,15k | 19,73k | Sale to Issuer | 4,75 | 82,12k | -4,81% |
| 2026-01-10 | Ms. Casi DeYoungChief Business Officer | -5,70k | 27,07k | Sale to Issuer | 4,75 | 39,12k | -12,72% |
| 2026-01-10 | Dr. Arunthathy Nirmalini PanditeChief Medical Officer | -6,85k | 32,54k | Sale to Issuer | 4,75 | 157,24k | -4,18% |
| 2026-01-10 | Mr. Andrew R. NeillCFO | -6,66k | 31,64k | Sale to Issuer | 4,75 | 185,10k | -3,47% |
| 2025-08-25 | OrbiMed Advisors LLCSociété | 6,31M | 5,47M | Achat | 0,87 | 6,31M | - |
| 2025-08-25 | OrbiMed Advisors LLCSociété | 30,57M | 0,00 | Open Market Derivative Acquisition | 0,00 - 1,08 | 3,07M | -111,18% |
| 2025-08-25 | Dr. Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | 12,81k | 11,11k | Achat | 0,87 | 86,28k | 17,43% |
| 2025-08-25 | Dr. Clay B. SiegallIndependent Director | 128,05k | 111,11k | Achat | 0,87 | 128,05k | - |
| 2025-08-25 | Mr. Andrew R. NeillCFO | 64,03k | 55,56k | Achat | 0,87 | 169,30k | 60,82% |
| 2025-08-25 | Dr. Taylor H. SchreiberCo-Founder, CEO & Director | 25,61k | 22,22k | Achat | 0,87 | 2,71M | 0,95% |
| 2025-08-25 | Dr. Abhinav A. ShuklaChief Technical Officer | 5,12k | 4,44k | Achat | 0,87 | 37,56k | 15,79% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
